<p>Immatics（纳斯达克股票代码：IMTX - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场开盘前发布其 2026 年第一季度财报。分析师预计该公司将宣布每股收益为（$0.42）以及该季度收入为 979.30 万美元。各方被鼓励查看该公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 13 日东部时间下午 12:30 的电话会议的最新信息。</p>
<p>Immatics（纳斯达克股票代码：IMTX - 获取免费报告）上一次发布季度财报是在 3 月 5 日星期四。该公司报告的季度每股收益为（$0.34），超出分析师一致预期的（$0.48）$0.14。该季度公司的收入为 2318 万美元，而一致预期为 1218 万美元。Immatics 的净利润率为-411.90%，股本回报率为-41.81%。分析师平均预计 Immatics 在当前财政年度的每股收益为-$1，下一财政年度的每股收益也为-$1。</p>
<h2>Immatics 股票表现</h2>
<p>在周二的午盘交易中，纳斯达克股票代码：IMTX 的股价下跌了$0.22，达到$10.93。该公司 219,242 股股票被交易，较其平均交易量 426,446 股有所减少。该公司的 50 日简单移动平均为$10.29，200 日简单移动平均为$10.11。该公司的市值为 14.6 亿美元，市盈率为-5.94，贝塔值为 1.31。Immatics 的 12 个月低点为$3.94，12 个月高点为$12.41。</p>
<h2>机构投资者对 Immatics 的看法</h2>
<p>几家大型投资者最近对该公司的持仓进行了调整。T. Rowe Price Investment Management Inc.在第四季度将其在 Immatics 的持股增加了 10.7%。T. Rowe Price Investment Management Inc.目前拥有 21,459,156 股该公司的股票，价值 225,322,000 美元，此前在上个季度购买了 2,075,987 股。Virtus Investment Advisers LLC 在第四季度将其在 Immatics 的持股增加了 43.0%。Virtus Investment Advisers LLC 目前拥有 26,497 股该公司的股票，价值 278,000 美元，此前在上个季度增持了 7,965 股。SummitTX Capital L.P.在第四季度将其在 Immatics 的持股增加了 117.7%。SummitTX Capital L.P.目前拥有 96,784 股该公司的股票，价值 1,016,000 美元，此前在上个季度增持了 52,318 股。Tudor Investment Corp ET AL 在第四季度购买了 Immatics 的新股份，价值约 575,000 美元。最后，Sphera Funds Management LTD.在第四季度将其在 Immatics 的持股增加了 47.7%。Sphera Funds Management LTD.目前拥有 861,105 股该公司的股票，价值 9,042,000 美元，此前在上个季度增持了 278,000 股。机构投资者持有该公司 64.41% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>IMTX 成为多份分析师报告的主题。Wall Street Zen 在周六将 Immatics 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 1 月 22 日星期四重申了对 Immatics 股票的 “卖出（d-）” 评级。TD Cowen 在 4 月 28 日星期二开始对 Immatics 的股票进行覆盖，并给予该股票 “买入” 评级。Jefferies Financial Group 在 3 月 16 日星期一开始对 Immatics 的股票进行覆盖，并给予该股票 “买入” 评级和$18.00 的目标价。最后，瑞穗证券在 2 月 19 日星期四对 Immatics 的股票设定了$25.00 的目标价。七位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Immatics 的平均评级为 “适度买入”，共识目标价为$19.00。</p>
<p><strong>查看我们对 IMTX 的最新分析</strong></p>
<h2>Immatics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immatics N.V. 纳斯达克：IMTX 是一家临床阶段的生物技术公司，致力于开发基于 T 细胞受体（TCR）的免疫疗法用于实体瘤。该公司利用其专有的发现和工程平台来识别肿瘤特异性肽靶点，并开发利用患者免疫系统力量的疗法。Immatics 的方法旨在通过引导 T 细胞识别并精准杀死癌细胞来产生持久的反应。</p>
<p>Immatics 技术套件的核心是 XPRESIDENT®平台，该平台挖掘癌症肽组，以发现自然呈现在癌细胞表面的新型肿瘤抗原。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Immatics 更具吸引力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1UWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Immatics 吗？</h2>
<p>在你考虑 Immatics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Immatics 并不在名单上。</p>
<p>虽然 Immatics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMTX

<p>Immatics（纳斯达克股票代码：IMTX）将于 5 月 12 日发布 2026 年第一季度财报，分析师预测每股亏损 0.42 美元，收入为 979 万美元。该公司在 2025 年第四季度报告的每股亏损为 0.34 美元，收入为 2318 万美元。机构投资者持有该股票的 64.41%。最近的分析师评级包括七个 “买入” 和一个 “卖出”。该股票目前交易价格为 10.93 美元，市值为 14.6 亿美元，市场共识目标价为 19.00 美元</p>

<p>Immatics (NASDAQ:IMTX - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $9.7930 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.</p>
<div class="lb-trans"><p>Immatics（纳斯达克股票代码：IMTX - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场开盘前发布其 2026 年第一季度财报。分析师预计该公司将宣布每股收益为（$0.42）以及该季度收入为 979.30 万美元。各方被鼓励查看该公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 13 日东部时间下午 12:30 的电话会议的最新信息。</p>
</div><p>Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.14. The company had revenue of $23.18 million during the quarter, compared to the consensus estimate of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Immatics（纳斯达克股票代码：IMTX - 获取免费报告）上一次发布季度财报是在 3 月 5 日星期四。该公司报告的季度每股收益为（$0.34），超出分析师一致预期的（$0.48）$0.14。该季度公司的收入为 2318 万美元，而一致预期为 1218 万美元。Immatics 的净利润率为-411.90%，股本回报率为-41.81%。分析师平均预计 Immatics 在当前财政年度的每股收益为-$1，下一财政年度的每股收益也为-$1。</p>
</div><h2>Immatics Stock Performance</h2>
<div class="lb-trans"><h2>Immatics 股票表现</h2>
</div><p>Shares of NASDAQ:IMTX traded down $0.22 during midday trading on Tuesday, reaching $10.93. 219,242 shares of the company's stock were exchanged, compared to its average volume of 426,446. The company's 50 day simple moving average is $10.29 and its two-hundred day simple moving average is $10.11. The firm has a market capitalization of $1.46 billion, a PE ratio of -5.94 and a beta of 1.31. Immatics has a 12 month low of $3.94 and a 12 month high of $12.41.</p>
<div class="lb-trans"><p>在周二的午盘交易中，纳斯达克股票代码：IMTX 的股价下跌了$0.22，达到$10.93。该公司 219,242 股股票被交易，较其平均交易量 426,446 股有所减少。该公司的 50 日简单移动平均为$10.29，200 日简单移动平均为$10.11。该公司的市值为 14.6 亿美元，市盈率为-5.94，贝塔值为 1.31。Immatics 的 12 个月低点为$3.94，12 个月高点为$12.41。</p>
</div><h2>Institutional Investors Weigh In On Immatics</h2>
<div class="lb-trans"><h2>机构投资者对 Immatics 的看法</h2>
</div><p>Several large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Immatics by 10.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company's stock worth $225,322,000 after purchasing an additional 2,075,987 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in Immatics by 43.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company's stock worth $278,000 after acquiring an additional 7,965 shares during the last quarter. SummitTX Capital L.P. grew its holdings in Immatics by 117.7% during the 4th quarter. SummitTX Capital L.P. now owns 96,784 shares of the company's stock worth $1,016,000 after acquiring an additional 52,318 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in Immatics during the 4th quarter worth about $575,000. Finally, Sphera Funds Management LTD. grew its holdings in Immatics by 47.7% during the 4th quarter. Sphera Funds Management LTD. now owns 861,105 shares of the company's stock worth $9,042,000 after acquiring an additional 278,000 shares during the last quarter. Institutional investors own 64.41% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近对该公司的持仓进行了调整。T. Rowe Price Investment Management Inc.在第四季度将其在 Immatics 的持股增加了 10.7%。T. Rowe Price Investment Management Inc.目前拥有 21,459,156 股该公司的股票，价值 225,322,000 美元，此前在上个季度购买了 2,075,987 股。Virtus Investment Advisers LLC 在第四季度将其在 Immatics 的持股增加了 43.0%。Virtus Investment Advisers LLC 目前拥有 26,497 股该公司的股票，价值 278,000 美元，此前在上个季度增持了 7,965 股。SummitTX Capital L.P.在第四季度将其在 Immatics 的持股增加了 117.7%。SummitTX Capital L.P.目前拥有 96,784 股该公司的股票，价值 1,016,000 美元，此前在上个季度增持了 52,318 股。Tudor Investment Corp ET AL 在第四季度购买了 Immatics 的新股份，价值约 575,000 美元。最后，Sphera Funds Management LTD.在第四季度将其在 Immatics 的持股增加了 47.7%。Sphera Funds Management LTD.目前拥有 861,105 股该公司的股票，价值 9,042,000 美元，此前在上个季度增持了 278,000 股。机构投资者持有该公司 64.41% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>IMTX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Immatics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Immatics in a report on Thursday, January 22nd. TD Cowen began coverage on shares of Immatics in a report on Tuesday, April 28th. They issued a &#34;buy&#34; rating on the stock. Jefferies Financial Group began coverage on shares of Immatics in a report on Monday, March 16th. They issued a &#34;buy&#34; rating and a $18.00 target price on the stock. Finally, Mizuho set a $25.00 target price on shares of Immatics in a report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Immatics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $19.00.</p>
<div class="lb-trans"><p>IMTX 成为多份分析师报告的主题。Wall Street Zen 在周六将 Immatics 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 1 月 22 日星期四重申了对 Immatics 股票的 “卖出（d-）” 评级。TD Cowen 在 4 月 28 日星期二开始对 Immatics 的股票进行覆盖，并给予该股票 “买入” 评级。Jefferies Financial Group 在 3 月 16 日星期一开始对 Immatics 的股票进行覆盖，并给予该股票 “买入” 评级和$18.00 的目标价。最后，瑞穗证券在 2 月 19 日星期四对 Immatics 的股票设定了$25.00 的目标价。七位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Immatics 的平均评级为 “适度买入”，共识目标价为$19.00。</p>
</div><p><strong>View Our Latest Analysis on IMTX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 IMTX 的最新分析</strong></p>
</div><h2>Immatics Company Profile</h2>
<div class="lb-trans"><h2>Immatics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immatics N.V. NASDAQ: IMTX is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient's immune system. Immatics' approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.</p>
<div class="lb-trans"><p>Immatics N.V. 纳斯达克：IMTX 是一家临床阶段的生物技术公司，致力于开发基于 T 细胞受体（TCR）的免疫疗法用于实体瘤。该公司利用其专有的发现和工程平台来识别肿瘤特异性肽靶点，并开发利用患者免疫系统力量的疗法。Immatics 的方法旨在通过引导 T 细胞识别并精准杀死癌细胞来产生持久的反应。</p>
</div><p>At the core of Immatics' technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.</p>
<div class="lb-trans"><p>Immatics 技术套件的核心是 XPRESIDENT®平台，该平台挖掘癌症肽组，以发现自然呈现在癌细胞表面的新型肿瘤抗原。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Immatics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Immatics 更具吸引力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1UWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immatics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Immatics 吗？</h2>
</div><p>Before you consider Immatics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Immatics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Immatics 并不在名单上。</p>
</div><p>While Immatics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immatics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immatics (IMTX) 将在周二公布季度收益